Open AccessPhase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor–Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)
Author(s) -
Maura N. Dickler,
William T. Barry,
Constance Cirrincione,
Matthew J. Ellis,
Mary Ellen Moynahan,
Federico Innocenti,
Arti Hurria,
Hope S. Rugo,
Diana Lake,
Olwen Hahn,
Bryan P. Schneider,
Debu Tripathy,
Lisa A. Carey,
Eric P. Winer,
Clifford A. Hudis
Publication year - 2016
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/9rf0-wj19
Subject(s) - letrozole , medicine , oncology , bevacizumab , hormone receptor , breast cancer , endocrine system , postmenopausal women , cancer , hormone , gynecology , tamoxifen , chemotherapy